Clinical experience of oral treatment with desmopressin in central diabetes insipidus
Journal
Tzu Chi Medical Journal
Journal Volume
9
Journal Issue
3
Pages
183-190
Date Issued
1997
Author(s)
Abstract
To elucidate the effects of oral desmopressin (DDAVP) on central diabetes insipidus, basal 24 hour-urine and its osmolality were determined in 8 patients after discontinuation of intranasal DDAVP for 24 hrs. Then, 100μg, 200μg, and 400 μg or oral DDAVP were given on the 2nd, 3rd and 4th days, respectively, and hourly urine and osmolality were monitored. Patients were treated with optimal doses, and asked to return to the clinic every week for 4 weeks. Twenty-four-hour urine amounts were recorded and their osmolalities were determined during each visit. The results showed that the baseline 24-hour urine amounts averaged 8770±4026 mL (mean±SD), and osmolality averaged 153.9±78.2 mOsm/Kg. In the dose titration test, urine amounts decreased remarkably after 2 to 4 hours, followed by a rebound, and then a gradual return to baseline levels. Urine osmolalities increased, peaking after 2 to 4 hours, then gradually returning to the baseline levels. During the follow-up period, daily amounts decreased to 2513±1355 mL, and urine osmolalities increased to 429.8±143.3 mOsm/Kg by the 4th week. The median intranasal DDAVP dose used daily before the clinical trial was 12.5 μg (range 8 to 50 μg). The median daily oral DDAVP dose used by the 4th week was 300 μg (range 200 to 2100 μg). One patient experienced transient arthralgia, one patient experienced transient abdominal pain, and another patient experienced temporary headaches and sleepiness. All the patients asked for continuation of the oral DDAVP treatment instaed of a return to the intranasal form. These results suggest that oral DDAVP is safe, effective and convenient for treatment of central diabetes insipidus.
SDGs
Other Subjects
desmopressin; abdominal pain; adolescent; adult; arthralgia; article; clinical article; controlled study; diabetes insipidus; drug efficacy; drug safety; female; headache; human; intranasal drug administration; male; serum osmolality; somnolence; taiwan; urine osmolality
Type
journal article